![Kathleen Glaub](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Kathleen Glaub
Chief Executive Officer at
CuraSen Therapeutics, Inc.
Net worth: - $ as of 2026-05-30
Profile
Ms. Kathleen S.
Glaub is a Chief Executive Officer at CuraSen Therapeutics, Inc. She is on the Board of Directors at IO Biotech ApS.
Ms. Glaub was previously employed as an Independent Director by Aligos Therapeutics, Inc., a Chairman by Escient Pharmaceuticals, Inc., an Independent Director by IO Biotech, Inc., an Independent Director by Codexis, Inc., a Chief Executive Officer & Director by Afferent Pharmaceuticals, Inc., a President by Plexxikon, Inc., a Chief Financial Officer & Senior Vice President by Cell Genesys, Inc., a Treasurer by Genentech, Inc., and a Principal by Intel Corp.
She received her undergraduate degree from the University of California, Berkeley and an MBA from Kellogg School of Management.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
IO BIOTECH, INC. -.--% | 2025-06-04 | 0 ( -.--% ) | - $ | 2026-05-30 |
Kathleen Glaub active positions
| Companies | Position | Start |
|---|---|---|
IO Biotech ApS
 IO Biotech ApS BiotechnologyHealth Technology Develops disruptive immune therapies | Director/Board Member | 2018-06-10 |
CuraSen Therapeutics, Inc.
 CuraSen Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company that develops novel treatments for psychiatric and neurodegenerative diseases | Chief Executive Officer | 2024-10-14 |
Former positions of Kathleen Glaub
| Companies | Position | End |
|---|---|---|
| IO BIOTECH, INC. | Director/Board Member | 2026-03-30 |
| CODEXIS, INC. | Director/Board Member | 2019-09-29 |
Afferent Pharmaceuticals, Inc.
 Afferent Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops novel, selective drugs for the treatment of a range of debilitating neurogenic disorders | Chief Executive Officer | 2016-06-30 |
Plexxikon, Inc.
 Plexxikon, Inc. Miscellaneous Commercial ServicesCommercial Services Provides clinical and medical drug discovery and development services | President | 2013-04-30 |
| ALIGOS THERAPEUTICS, INC. | Director/Board Member | - |
Training of Kathleen Glaub
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
22
1st degree connections
13
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 13 |
|---|---|
Cell Genesys, Inc.
 Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Develops human disease therapies based on innovative gene modification technologies | Health Technology |
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops medicines for cancer peoples | Health Technology |
Intel Corp.
 Intel Corp. SemiconductorsElectronic Technology Engages in design, development, manufacture and sale of CPUs and integrated circuits to computing and related end products | Electronic Technology |
Plexxikon, Inc.
Plexxikon, Inc. Miscellaneous Commercial ServicesCommercial Services Provides clinical and medical drug discovery and development services | Commercial Services |
Codexis, Inc.
 Codexis, Inc. Chemicals: SpecialtyProcess Industries Develops biocatalytic chemical processes | Process Industries |
Afferent Pharmaceuticals, Inc.
Afferent Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops novel, selective drugs for the treatment of a range of debilitating neurogenic disorders | Health Technology |
University of California, Berkeley
 University of California, Berkeley Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Kellogg School of Management
 Kellogg School of Management Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
IO Biotech ApS
IO Biotech ApS BiotechnologyHealth Technology Develops disruptive immune therapies | Health Technology |
CuraSen Therapeutics, Inc.
CuraSen Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company that develops novel treatments for psychiatric and neurodegenerative diseases | Health Technology |
Escient Pharmaceuticals, Inc.
 Escient Pharmaceuticals, Inc. BiotechnologyHealth Technology Operates as a drug discovery and development company | Health Technology |
Aligos Therapeutics, Inc.
 Aligos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops targeted, curative therapies for hepatologic diseases and viral infections | Health Technology |
IO Biotech, Inc.
 IO Biotech, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company that develops novel, immune-modulating cancer therapies | Health Technology |
- Stock Market
- Insiders
- Kathleen Glaub
